Login to Your Account

Pharma: Clinic Roundup

Thursday, March 29, 2012
• Allergan Inc., of Irvine, Calif., said two Phase III trials of Botox (onabotulinumtoxinA) met their primary endpoints in overactive bladder, with data from both studies showing that Botox significantly reduced urinary incontinence episodes compared to placebo in patients not adequately managed by an anticholinergic treatment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription